Compare · GPCR vs VKTX
GPCR vs VKTX
Side-by-side comparison of Structure Therapeutics Inc. (GPCR) and Viking Therapeutics Inc. (VKTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GPCR and VKTX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- VKTX is the larger of the two at $3.73B, about 2.6x GPCR ($1.43B).
- VKTX has been more active in the news (6 items in the past 4 weeks vs 5 for GPCR).
- VKTX has more recent analyst coverage (24 ratings vs 16 for GPCR).
- Company
- Structure Therapeutics Inc.
- Viking Therapeutics Inc.
- Price
- -
- -
- Market cap
- $1.43B
- $3.73B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2023
- 2015
- News (4w)
- 5
- 6
- Recent ratings
- 16
- 24
Viking Therapeutics Inc.
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRÃ), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRÃ for X-linked adrenoleukodystrophy. Viking Therapeutics, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Latest GPCR
- SEC Form 10-Q filed by Structure Therapeutics Inc.
- Structure Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Structure Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
- Amendment: SEC Form SCHEDULE 13G/A filed by Structure Therapeutics Inc.
- Structure Therapeutics to Participate in the Jefferies Global Healthcare Conference
- Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2026
- CHIEF MEDICAL OFFICER Coll Crespo Blas covered exercise/tax liability with 10,626 units of Ordinary Shares, decreasing direct ownership by 8% to 258,228 units (SEC Form 4) (for tax liability)
- Structure Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management
- Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences
Latest VKTX
- Viking Therapeutics Announces Two Poster Presentations at ObesityWeek® 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by Viking Therapeutics Inc.
- Viking Therapeutics to Participate at Upcoming Investor Conferences
- SEC Form 10-Q filed by Viking Therapeutics Inc.
- SEC Form 8-K filed by Viking Therapeutics Inc.
- Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
- Viking Therapeutics to Report Financial Results for Third Quarter 2026 on October 28, 2026
- UBS initiated coverage on Viking Therapeutics with a new price target
- Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesity
- Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity